免疫检查点疗效的预测性生物标志物：多组学能否打破僵局？ - Suppr

Predictive biomarkers for immune checkpoint efficacy: is multi-omics breaking the deadlock?

作者信息

Mogenet Alice, Greillier Laurent, Tomasini Pascale

机构信息

Multidisciplinary Oncology and Therapeutic Innovations Department, Assistance Publique - Hôpitaux de Marseille, Marseille, France.

Aix Marseille University, CNRS, INSERM, Predictive Oncology Department, CRCM, Marseille, France.

出版信息

Transl Lung Cancer Res. 2024 Oct 31;13(10):2856-2860. doi: 10.21037/tlcr-24-594. Epub 2024 Oct 17.

DOI:10.21037/tlcr-24-594

PMID:39507024

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11535845/

Abstract

摘要

相似文献

Predictive biomarkers for immune checkpoint efficacy: is multi-omics breaking the deadlock?免疫检查点疗效的预测性生物标志物：多组学能否打破僵局？

Transl Lung Cancer Res. 2024 Oct 31;13(10):2856-2860. doi: 10.21037/tlcr-24-594. Epub 2024 Oct 17.

Multi-omics indicators of long-term survival benefits after immune checkpoint inhibitor therapy.免疫检查点抑制剂治疗后长期生存获益的多组学指标。

Cell Rep Methods. 2023 Oct 23;3(10):100596. doi: 10.1016/j.crmeth.2023.100596. Epub 2023 Sep 21.

Progress and Challenges of Immunotherapy Predictive Biomarkers for Triple Negative Breast Cancer in the Era of Single-Cell Multi-Omics.单细胞多组学时代三阴性乳腺癌免疫治疗预测生物标志物的进展与挑战

Life (Basel). 2023 May 16;13(5):1189. doi: 10.3390/life13051189.

Identifying biomarkers associated with immunotherapy response in melanoma by multi-omics analysis.通过多组学分析鉴定与黑色素瘤免疫治疗反应相关的生物标志物。

Comput Biol Med. 2023 Dec;167:107591. doi: 10.1016/j.compbiomed.2023.107591. Epub 2023 Oct 18.

Multi-omics reveals novel prognostic implication of SRC protein expression in bladder cancer and its correlation with immunotherapy response.多组学揭示 SRC 蛋白表达在膀胱癌中的新型预后意义及其与免疫治疗反应的相关性。

Ann Med. 2021 Dec;53(1):596-610. doi: 10.1080/07853890.2021.1908588.

Cutaneous immune-related adverse events to immune checkpoint inhibitors: from underlying immunological mechanisms to multi-omics prediction.免疫检查点抑制剂相关的皮肤免疫不良反应：从潜在的免疫学机制到多组学预测。

Front Immunol. 2023 Jun 22;14:1207544. doi: 10.3389/fimmu.2023.1207544. eCollection 2023.

The Comprehensive "Omics" Approach from Metabolomics to Advanced Omics for Development of Immune Checkpoint Inhibitors: Potential Strategies for Next Generation of Cancer Immunotherapy.从代谢组学到高级组学的全面“组学”方法在免疫检查点抑制剂开发中的应用：下一代癌症免疫疗法的潜在策略。

Int J Mol Sci. 2021 Jun 28;22(13):6932. doi: 10.3390/ijms22136932.

Mechanism and potential predictive biomarkers of immune checkpoint inhibitors in NSCLC.非小细胞肺癌免疫检查点抑制剂的作用机制及潜在预测生物标志物。

Biomed Pharmacother. 2020 Jul;127:109996. doi: 10.1016/j.biopha.2020.109996. Epub 2020 May 6.

Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study.淋巴细胞亚群与晚期非小细胞肺癌免疫检查点抑制剂治疗疗效和预后的相关性：一项回顾性研究。

BMC Pulm Med. 2022 Apr 28;22(1):166. doi: 10.1186/s12890-022-01951-x.

Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy.多组学预测免疫检查点治疗期间的免疫相关不良事件。

Nat Commun. 2020 Oct 2;11(1):4946. doi: 10.1038/s41467-020-18742-9.

引用本文的文献

Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches.癌症中的免疫逃逸：机制与前沿治疗方法。

Signal Transduct Target Ther. 2025 Jul 31;10(1):227. doi: 10.1038/s41392-025-02280-1.

本文引用的文献

PD-1/LAG-3 co-signaling profiling uncovers CBL ubiquitin ligases as key immunotherapy targets.PD-1/LAG-3 共信号通路分析揭示 CBL 泛素连接酶为免疫治疗的关键靶点。

EMBO Mol Med. 2024 Aug;16(8):1791-1816. doi: 10.1038/s44321-024-00098-y. Epub 2024 Jul 19.

The impact of Foxp3 regulatory T-cells on CD8 T-cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors.Foxp3调节性T细胞对肿瘤微环境中CD8 T细胞功能障碍及免疫检查点抑制剂反应的影响。

Br J Pharmacol. 2024 Feb 7. doi: 10.1111/bph.16313.

Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial.多组学分析揭示了来自III期肺癌MAP S1400I试验的鳞状细胞肺癌患者中与免疫治疗获益相关的免疫特征。

Clin Cancer Res. 2024 Apr 15;30(8):1655-1668. doi: 10.1158/1078-0432.CCR-23-0251.

Nivolumab receptor occupancy on effector regulatory T cells predicts clinical benefit.纳武利尤单抗在效应调节性 T 细胞上的受体占有率预测临床获益。

Cancer Sci. 2024 Mar;115(3):752-762. doi: 10.1111/cas.16061. Epub 2024 Jan 22.

Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancer.免疫排斥常数作为预测免疫检查点抑制剂在非小细胞肺癌中的疗效的生物标志物。

J Transl Med. 2023 Sep 19;21(1):637. doi: 10.1186/s12967-023-04463-2.

Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study.帕博利珠单抗联合培美曲塞和铂类化疗用于非鳞状非小细胞肺癌：III 期 KEYNOTE-189 研究的 5 年结果。

J Clin Oncol. 2023 Apr 10;41(11):1992-1998. doi: 10.1200/JCO.22.01989. Epub 2023 Feb 21.

LRP1B is a Potential Biomarker for Tumor Immunogenicity and Prognosis of HCC Patients Receiving ICI Treatment.LRP1B是接受免疫检查点抑制剂治疗的肝癌患者肿瘤免疫原性和预后的潜在生物标志物。

J Hepatocell Carcinoma. 2022 Mar 22;9:203-220. doi: 10.2147/JHC.S348785. eCollection 2022.

Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer.人工智能驱动的肿瘤浸润淋巴细胞空间分析作为非小细胞肺癌免疫检查点抑制的补充生物标志物

J Clin Oncol. 2022 Jun 10;40(17):1916-1928. doi: 10.1200/JCO.21.02010. Epub 2022 Mar 10.

Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial.纳武利尤单抗联合伊匹单抗对比纳武利尤单抗用于治疗既往接受过治疗的 IV 期鳞状细胞肺癌患者：Lung-MAP S1400I 期随机临床研究。

JAMA Oncol. 2021 Sep 1;7(9):1368-1377. doi: 10.1001/jamaoncol.2021.2209.

Predictive biomarkers for response to immune checkpoint inhibition.免疫检查点抑制反应的预测生物标志物。

Semin Cancer Biol. 2022 Feb;79:4-17. doi: 10.1016/j.semcancer.2021.03.036. Epub 2021 Apr 2.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Predictive biomarkers for immune checkpoint efficacy: is multi-omics breaking the deadlock?

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献